363 related articles for article (PubMed ID: 20819892)
41. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
42. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
Bihari I; Pánczél G; Kovacs J; Beygo J; Fragapane E
Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
[TBL] [Abstract][Full Text] [Related]
43. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
45. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
46. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
[TBL] [Abstract][Full Text] [Related]
47. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
48. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
[TBL] [Abstract][Full Text] [Related]
49. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
50. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
Esposito S; D'Angelo E; Daleno C; Peia F; Scala A; Serra D; Mirra N; Galeone C; Principi N
Vaccine; 2010 Nov; 28(50):7825-8. PubMed ID: 20888873
[TBL] [Abstract][Full Text] [Related]
52. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
53. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
54. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
[TBL] [Abstract][Full Text] [Related]
55. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
El Sahly H
Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
[TBL] [Abstract][Full Text] [Related]
56. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
[TBL] [Abstract][Full Text] [Related]
58. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
59. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
[TBL] [Abstract][Full Text] [Related]
60. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]